TD Cowen lowered the firm’s price target on BioLife Solutions to $20 from $25 and keeps an Outperform rating on the shares. The firm noted they announced a new CEO, gave guidance at the lower end with preliminarty Q3 revenues in line, and an insider purchase to show support.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BLFS:
- BioLife Solutions reports Q3 preliminary revenue $33.3 M, consensus $32.72M
- BioLife Solutions names Garrie Richardson Chief Revenue Officer
- BioLife Solutions names Roderick de Greef Chairman and CEO, replacing Rice
- BioLife Solutions Announces Leadership Transitions & Preliminary Third Quarter Revenue with Updated Outlook for 2023